Dupilumab associated with "highly favorable" outcomes in Type 2 Chronic Rhinosinusitis Aditi6 Oct 2022 10:30 AM ISTSwitzerland: A recent study published in Allergy, European Journal of Allergy and Clinical Immunology, predicted treatment outcome as "highly...
FDA approves dupilumab as first and only treatment Indicated for Prurigo Nodularis Dr. Kamal Kant Kohli2 Oct 2022 7:30 PM ISTPrurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest...
Sanofi Prurigo nodularis drug Dupixent gets USFDA okay Ruchika Sharma30 Sept 2022 4:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (USFDA) has approved Dupixent (dupilumab) for the treatment of adult patients...
Dupilumab significantly improves skin lesions and itching among treated patients with prurigo nodularis Dr. Kamal Kant Kohli21 Sept 2022 8:00 PM ISTDupilumab improves skin lesions and itching among treated patients with prurigo nodularis, reveals Initrial data presented at the European Academy of...
Sanofi, Regeneron Pharma announce positive Phase 3 data for Dupixent in adults with uncontrolled prurigo nodularis Ruchika Sharma10 Sept 2022 12:56 PM ISTPeople with prurigo nodularis experience intense, persistent itch, with thick skin lesions (called nodules) that can cover most of the body.
JAK inhibitors don't increase risk of VTE in Atopic Dermatitis patients: JAMA Dr.Niharika Harsha B30 Aug 2022 8:00 PM ISTThe use of JAK Inhibitors does not increase the risk of Venous thromboembolism in patients with Atopic Dermatitis as per a new study that was...
Abrocitinib bests dupilumab for treating moderate-to-severe atopic dermatitis: Lancet Dr. Shravani Dali18 Aug 2022 11:15 AM ISTAbrocitinib 200 mg per day is more efficacious than dupilumab in adults with moderate-to-severe atopic dermatitis according to a recent study...
Eczema drug dupilumab increases survival in COVID-19 patients Dr. Kamal Kant Kohli18 Aug 2022 11:00 AM ISTDupilumab a monoclonal antibody used to treat asthma and eczema can improve survival for patients with moderate to severe COVID-19, finds a clinical...
Sanofi gets CDSCO Panel okay to study Dupilumab Dr. Divya Colin19 July 2022 6:00 PM ISTNew Delhi: Directing to include all Serious Adverse Events (SAEs) and adverse events (AEs) of test drug in the informed consent document, the Subject...
Sanofi Dupixent Phase 3 trial shows positive results in children with eosinophilic esophagitis as young as age 1 Ruchika Sharma16 July 2022 12:30 PM ISTEoE is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.
Clinical Characteristics and Treatment of Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients Dr Ishan Kataria3 July 2022 8:00 PM ISTDupilumab has been approved by the Food and Drug Administration (FDA) to treat adults with moderate-to-severe atopic dermatitis (AD) that is...
Sanofi Dupixent wins USFDA nod for atopic dermatitis Ruchika Sharma8 Jun 2022 1:00 PM ISTDupixent is administered as an injection under the skin (subcutaneous injection) at different injection sites.
